Publications by authors named "Hiroko Bando"

Claim this Profile
E
Efficacy and Safety of Mirogabalin Therapy for Paclitaxel-Induced Peripheral Neuropathy (MICHEL Study): A Pilot Study.
Hiroko Bando, Aya Sawa, Hiroko Bando, Riko Sato, Tomohei Matsuo

Oncology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective multi-center cohort study investigating safety of sentinel lymph node biopsy for axillary staging in clinical T3-4c breast cancer.
Sayaka Kuba, Yasuaki Sagara, Hiroshi Yano, Shigeto Maeda, Takehiko Sakai, Hiroko Bando

Breast Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of endometrial cancer among breast cancer survivors in Japan: a matched cohort study.
Chitose Kawamura, Krishnan Bhaskaran, Takaaki Konishi, Yasuaki Sagara, Hiroko Bando

Breast Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined use of iPTH and D/W ratio in preoperative diagnosis of parathyroid carcinoma.
Tomohei Matsuo, Akiko Iguchi-Manaka, Aya Sawa, Mai Okazaki, Sachie Hashimoto, Hiroko Bando

Surg Today· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct follicular T cell subsets regulate lymphoma progression and outcomes.
Yoshiaki Abe, Junko Zenkoh, Akinori Kanai, Daisuke Ikeda, Daisuke Kaji, Hiroko Bando

Cancer Cell· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refining compression therapy for the prevention of chemotherapy-induced peripheral neuropathy in breast cancer patients: a sub-analysis of patient-reported discomfort and usability.
Mai Okazaki, Aya Ueda, Akiko Iguchi-Manaka, Bryan J Mathis, Kensuke Shimada, Hiroko Bando

BMC Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.
Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, Yukiko Kajiwara, Mitsugu Yamamoto, Hiroko Bando

Breast Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26).
Hiroko Bando, Aya Ueda, Kaori Terata, Mihoko Doi, Shigenori E Nagai

Breast Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-Myc Overexpression in Adolescent and Young Adult Breast Cancer: Distinct From Older Adults With Relevantly Expressed Cholecystokinin B Receptor.
Tomoyuki Tanino, Yoko Nakanishi, Haruna Nishimaki-Watanabe, Fumi Nozaki, Sumie Ohni, Hiroko Bando

Pathol Int· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel-induced Peripheral Neuropathy and Quality of Life: Sub-analysis of the MICHEL Study.
Aya Sawa, Riko Sato, Tomohei Matsuo, Mai Okazaki, Sachie Hashimoto, Hiroko Bando

Anticancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.
Takayuki Ueno, Louis W C Chow, Wonshik Han, Chiun Sheng Huang, G Bruce Mann, Hiroko Bando

Endocr Relat Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-expressed GPNMB orchestrates Siglec-9 TAM polarization and EMT to promote metastasis in triple-negative breast cancer.
Thuy Linh Dang Cao, Kunio Kawanishi, Sachie Hashimoto, Kowit Hengphasatporn, Chiaki Nagai-Okatani, Hiroko Bando

Proc Natl Acad Sci U S A· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, Yukiko Kajiwara, Mitsugu Yamamoto, Hiroko Bando

Breast Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.
Mitsue Saito, Hirotoshi Iihara, Mototsugu Shimokawa, Ryoko Udagawa, Michiko Tsuneizumi, Hiroko Bando

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer.
Yukari Ando, Hiroko Miyadera, Hiroko Bando, Sachie Hashimoto, Emiko Noguchi

BMC Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Utility of Integrated Multidisciplinary Patient-Centered Information in Breast Cancer Care: A Mixed Methods Study.
Atsuko Sugiyama, Kazuki Utsunomiya, Katsuhiko Fujimoto, Hiroko Bando

J Multidiscip Healthc· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-cancer risks among female breast cancer survivors: a matched cohort study in Japan.
Chitose Kawamura, Krishnan Bhaskaran, Takaaki Konishi, Yasuaki Sagara, Hiroko Bando

Lancet Reg Health West Pac· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Change in Breast Cancer Screening Participation during COVID-19 Based on the 2019 and 2022 Comprehensive Survey of Living Conditions in Japan.
Chitose Kawamura, Masao Iwagami, Jun Komiyama, Yuta Taniguchi, Yu Sun, Hiroko Bando

JMA J· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.
Tomomi Nishimura, Ravi Velaga, Norikazu Masuda, Kosuke Kawaguchi, Shuji Kawaguchi, Hiroko Bando

Cancer Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Online Survey about Communication between Abemaciclib-Treated Patients with Breast Cancer and Physicians].
Chihiro Iseki, Naoko Toriguchi, Yoshinori Tanizawa, Nobuyuki Sekine, Seiko Mizuno, Hiroko Bando

Gan To Kagaku Ryoho· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective disruption of cancer cell membranes by photodynamic therapy with cell membrane-adhesive photosensitizer.
Aoi Hoshi, Toru Yoshitomi, Yoshiki Komatsu, Naoki Kawazoe, Guoping Chen, Hiroko Bando

J Clin Biochem Nutr· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts.
Shin Takahashi, Nobuaki Sato, Kouji Kaneko, Norikazu Masuda, Masaaki Kawai, Hiroko Bando

Transl Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consideration of factors of low accrual and methods for setting appropriate accrual periods: Japan Clinical Oncology Group study.
Keita Sasaki, Junki Mizusawa, Hiroko Bando, Kenichi Nakamura, Tomoko Kataoka

Trials· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Experience with Simultaneous Mixed Infusion of Trastuzumab and Pertuzumab in the Neo-Peaks Study (JBCRG-20 Sub-Study).
Hiroko Bando, Hiroyuki Yasojima, Kazushige Ishida, Kokoro Kobayashi, Hiroi Kasai

Gan To Kagaku Ryoho· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward a Patient-Centered Care Supporting System: Integration of Multidisciplinary Health Records in Breast Cancer Care.
Atsuko Sugiyama, Kazuki Utsunomiya, Hayato Okumiya, Katsuhiko Fujimoto, Yuka Shimomura, Hiroko Bando

Stud Health Technol Inform· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis